Axogen (AXGN) said Thursday it has priced an underwritten public offering of about 4.9 million shares at $42.50 each, with gross proceeds expected to be about $208.7 million.

Underwriters have been granted a 30-day option to purchase up to 736,500 additional shares.

The offering is expected to close on Friday.

The company plans to use the net proceeds from the offering to fund the acquisition of BioCircuit Technology, with the remaining proceeds to be used for general corporate purposes.